Hua Medicine (HKSE:02552) EPS (Basic) : HK$-0.27 (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine EPS (Basic)?

Hua Medicine's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was HK$-0.11. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.27.

Hua Medicine's EPS (Diluted) for the six months ended in Dec. 2024 was HK$-0.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.27.

Hua Medicine's EPS without NRI for the six months ended in Dec. 2024 was HK$-0.11. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Hua Medicine EPS (Basic) Historical Data

The historical data trend for Hua Medicine's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine EPS (Basic) Chart

Hua Medicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-0.49

-0.42

-0.24

-0.27

Hua Medicine Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial												-0.11	-0.10	-0.14	-0.16	-0.11

Hua Medicine EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Hua Medicine's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-267.072	-	0)	/	981.392
	=	-0.27

Hua Medicine's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-115.205	-	0)	/	982.137
	=	-0.12

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.27

Hua Medicine (HKSE:02552) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hua Medicine EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Hua Medicine's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hua Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » EPS (Basic)

Traded in Other Exchanges

N/A

Address

Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.huamedicine.com

Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.

Executives

Chen Li	2101 Beneficial owner
Hlyy Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
Hong Jane Xingfang	2202 Interest of your spouse
Wuxi Pharmatech Investments (cayman) Inc.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.	2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited	2201 Interest of corporation controlled by you
Nelsen Robert Taylor	2101 Beneficial owner
Venrock Management V, Llc	2102 Investment manager
Harvest Yuanxiang (cayman) Limited	2101 Beneficial owner
Arch Venture Fund Vii, L.p.	2101 Beneficial owner

Hua Medicine Headlines

No Headlines